Strategic Intelligence: Precision and Personalized Medicine - Advanced Therapeutics

Precision and personalized medicine (PPM) has already begun to reshape disease treatment paradigms and the provision of healthcare.

Gene-modified cell therapies are emerging as a cornerstone modality within PPM.

Cell therapies are entering a rapid growth phase across oncology and regenerative medicine.

Gene therapy remains a blockbuster-led modality with expanding therapeutic reach.

Antisense oligonucleotides are emerging as a fast-growing modality within PPM.

Oncolytic virus therapies show emerging commercial traction but remain a niche modality.

Core precision medicine enablers are strengthening adoption.

Scope

• This report talks about how precision and personalized medicine (PPM) has already begun to reshape disease treatment paradigms and the provision of healthcare.
• Improved patient outcomes, increased quality of life, reduced financial and time expenditure of disease management with curative therapies, and a shift from reactive to proactive care are all driving investment in R&D in this space.